C alcineurin inhibition (CNI), a cornerstone of immunosuppressive therapy after heart transplantation, with agents such as cyclosporine (CyA) and/or tacrolimus, is known to cause endothelial dysfunction by decreasing NO production, increasing endothelin-1 production, and increasing sensitivity to endothelin-1. [1] [2] [3] [4] [5] Both altered NO homeostasis and exposure to endothelin-1 lead to the endothelial production of inflammatory cytokines 6, 7 and activate inflammatory cell signaling pathways such as the nuclear factor-B (NF-B) pathway. 8 This endothelial inflammatory response includes the expression of cell adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) that allow circulating neutrophils to adhere to sites of endothelial injury. 9 -11 Epidermal growth factor-like domain 7 (Egfl7) is a novel protein that has been found to be expressed exclusively by endothelial and early endothelial progenitor cells. 12, 13 Studies in animal models of arterial injury have demonstrated Egfl7 to be upregulated in the regenerating endothelium after injury and have shown that it acts as a chemoattractant for embryonic endothelial cells. 14 Upregulation of Egfl7 gene expression has also been demonstrated in the brains of neonatal rats subjected to global hypoxic preconditioning. 15 Overexpression of Egfl7 in pulmonary artery endothelial cells has been demonstrated to be protective against hyperoxic injury in both animal and cell culture models. 16 We have recently demonstrated that Egfl7 inhibits endothelial ICAM-1 expression in response to hypoxia/reoxygenation injury. 17 Although the cell signaling pathways that mediate Egfl7 actions are unclear, recent evidence suggests that Egfl7 may be an inhibitor of the Notch signaling pathway. 18 Whether CNI directly influences neutrophil adhesion to coronary artery endothelial cells has not been reported previously. The role of Egfl7 in the context of endothelial activation in response to CNI injury has not been studied. We hypothesized that exposure to CNI would upregulate neutrophil adhesion to cultured human coronary artery endothelial cells (HCAECs). We also hypothesized that Egfl7 would have a protective effect against CNI-induced ICAM-1 expression via inhibition of activation of the NF-B signaling pathway. In addition, we hypothesized that the Notch receptor agonist Jagged1 would inhibit the effect of Egfl7 on neutrophil adhesion, ICAM-1 production, and NF-B activation.
Methods

Endothelial Cell Cultures
HCAECs (Lonza, Walkersville, MD) were cultured in endothelial growth medium (EGM-2 MV; Lonza) that contained endothelial growth factors, 5% fetal bovine serum, 100 U/mL penicillin, and 100 g/mL streptomycin at 37°C in humidified air (21% O 2 , 5% CO 2 , 74% N 2 ). Cells passaged 3 to 5 times and at 80% to 90% confluence were used for the present study.
Neutrophil Isolation
Neutrophils were isolated from the peripheral blood of healthy donors as described elsewhere. 19 Briefly, peripheral blood was drawn into 8-mL Vacutainer CPTs that contained sodium citrate (BD Diagnostics, Franklin Lakes, NJ). After centrifugation for 25 minutes at 1700g at room temperature, the plasma and peripheral blood mononuclear cell layer were discarded, and the gel lock was washed twice with ice-cold PBS. A 3-mL syringe attached to an 18-gauge 1.5-inch needle was then used to collect the erythrocyte/neutrophil mixture. The cells were collected in a 50-mL conical tube and washed with 5 mL of ice-cold PBS that contained 2% FBS. After centrifugation for 10 minutes at 400g at 4°C, the supernatant was aspirated off, and 16 mL of red blood cell lysis buffer (10 mmol/L KHCO 3 , 150 mmol/L NH 4 Cl, 0.1 mmol/L EDTA, pH 8.0) was added for 10 minutes at room temperature with intermittent vortexing. The cells were then washed with 5 mL of ice-cold PBS that contained 2% FBS. After centrifugation for 10 minutes at 400g at 4°C, the supernatant was aspirated off, and the cells were suspended in RPMI 1640 medium (Invitrogen, Carlsbad, CA) that contained 10% FBS, 50 U/mL penicillin G, 50 g/mL streptomycin, 50 g/mL gentamicin, 2.5 g/mL amphotericin B, 4 mmol/L L-glutamine, and 1% MEM nonessential amino acids solution, counted, and checked for viability by trypan blue exclusion.
We first examined the effect of CNI on neutrophil adhesion to treated HCAECs. Cells were subjected to 48 hours of treatment with CyA (0.1 to 10 g/mL; LC Laboratories, Woburn, MA), tacrolimus (1 to 100 ng/mL; LC Laboratories), recombinant human Egfl7 (100 ng/mL; Abnova, Taipei, Taiwan), and recombinant human Jagged1 (200 ng/mL; R&D Systems, Minneapolis, MN), alone or in combination. DMSO (0.01%) was used as the vehicle control for both CyA and tacrolimus, whereas PBS was used as the vehicle control for Egfl7 and Jagged1. A nonstatic neutrophil adhesion assay was then performed as detailed below. We next examined the effect of tacrolimus (100 ng/mL for 48 hours) in the presence and absence of Egfl7 (100 ng/mL) on ICAM-1 expression by both Western immunoblotting and flow cytometry. Additionally, the effect of Egfl7 (100 ng/mL) and Jagged1 (200 ng/mL) cotreatment with tacrolimus and CyA on cell-surface ICAM-1 expression was determined by flow cytometry. To examine the effect of Egfl7 on activation of the NF-B signaling pathway in response to CNI injury, nuclear proteins were isolated from cells that had been subjected to CNI injury with or without Egfl7 and were subjected to an NF-B DNA-binding activity assay as detailed below. Finally, cell viability was assessed with an XTT assay per the manufacturer's directions (Cell Prolifer-ation Kit II [XTT]; Roche Applied Science, Mannheim, Germany). XTT is a tetrazolium derivative that measures cell viability based on the activity of mitochondrial enzymes in live cells that reduce XTT to an orange formazan dye that can be quantified spectrophotometrically. Recombinant human tumor necrosis factor-␣ (1 ng/mL; R&D Systems) was used as a positive control in these studies.
Neutrophil Adhesion Assay
Neutrophil adhesion to confluent HCAEC monolayers grown on 24-well plates that had been subjected to CNI treatment with or without Egfl7 and/or Jagged1 was assessed with a nonstatic adhesion assay. Neutrophils isolated from healthy donors were resuspended in RPMI 1640 medium (1ϫ10 6 neutrophils/mL). After the wells that contained HCAEC monolayers were washed with PBS, 500 L of neutrophil suspension was added to each well. The plates were incubated for 1 hour at 37°C under rotating conditions (62 rpm). Nonadherent cells were then gently washed off twice with PBS, and the number of neutrophils remaining was quantified with a myeloperoxidase assay as described elsewhere. 20, 21 Briefly, 300 L of a solution of 5.5 mmol/L o-phenylenediamine and 4 mmol/L H 2 O 2 in a buffer that contained 67 mmol/L Na 2 PO 4 , 35 mmol/L citric acid, 0.1% Triton-X100, pH 5.0, was added to each well. The reaction was stopped after 4 minutes by the addition of 300 L of 1 mol/L H 2 SO 4 . Absorbance at 492 nm was then measured. Standard dilutions of neutrophils were used to construct a standard curve.
Western Immunoblotting
Western immunoblotting was performed with chemiluminescence detection. Protein samples were separated with 4% stacking and 10% running Tris-glycine SDS-PAGE gels. Proteins were then transferred to polyvinylidene fluoride membranes. Blocking was performed in 5% milk solution for 1 hour at room temperature. A monoclonal primary antibody for ICAM-1 (R&D Systems) was used at 1:5000 dilution in 1% milk. A secondary horseradish peroxidase-conjugated antibody was used at a concentration of 1:5000 (Santa Cruz Biotechnology, Santa Cruz, CA) with ECL Plus used as a substrate (GE Healthcare, Little Chalfont, UK). ␤-Actin was detected as a loading control for all blots. X-ray films were analyzed with a Bio-Rad GS-800 calibrated densitometer and Bio-Rad Quantity One software (Bio-Rad Laboratories, Hercules, CA).
Flow Cytometry
Flow cytometry was performed on cells grown on 60-mm plates detached and stained as follows: Cells were washed twice with PBS, then incubated with 1 mL of Accutase cell detachment medium (eBioscience, San Diego, CA) at 37°C for 2 to 10 minutes to detach the cells. Once detached, 2 mL of staining buffer (1% bovine serum albumin and 20 mmol/L glucose in PBS) was added to the cell suspension, which was then divided into samples for ICAM-1 and isotype IgG staining. The samples were centrifuged at 400g for 5 minutes at 4°C, and resultant cell pellets were then resuspended in 100 L of staining buffer that contained a 1:100 dilution of either ICAM-1 monoclonal antibody or IgG 1 isotype control antibody (R&D Systems). The samples were incubated on ice for 40 minutes, washed with 1 mL of staining buffer, and centrifuged at 400g for 5 minutes at 4°C. The cell pellets were resuspended in 100 L of staining buffer that contained a 1:500 dilution of secondary antibody (Alexa Fluor 488, Invitrogen). The samples were incubated on ice in the dark for 25 minutes, washed with 1 mL of staining buffer, and centrifuged at 400g for 5 minutes at 4°C. The samples were then fixed in 2% paraformaldehyde and resuspended in 200 L of staining buffer. Cell-surface ICAM-1 expression on Ն15 000 cells was analyzed with a flow cytometer (Coulter EPICS XL, Beckman Coulter, Brea, CA), and data analysis was performed with FlowJo software (version 7.2.5, Tree Star Inc, Ashland, OR).
NF-B DNA-Binding Activity Assay
Nuclear extracts were obtained from cell pellets with an NE-PER extraction kit (Thermo Scientific, Rockford, IL) per the manufacturer's directions. NF-B DNA-binding activity within the nuclear fraction was determined with an NF-B (p65) transcription factor activity assay kit (Cayman Chemical Company, Ann Arbor, MI) per the manufacturer's directions.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism software (version 5.0, GraphPad Software, La Jolla, CA). Continuous data are expressed as meanϮSD. A 1-way ANOVA with post hoc pairwise comparisons between all groups was performed with Bonferroni correction for all data.
Results
Egfl7 Inhibits Neutrophil Adhesion to HCAECs After CNI Treatment
Exposure of HCAECs to 48 hours of treatment with CyA and tacrolimus (nϭ8/group) increased neutrophil adhesion (Figure 1A) . Incubation with either Egfl7 or Jagged1 (nϭ12/ group) alone had no significant effect on neutrophil adhesion ( Figure 1A ). HCAEC cotreatment with Egfl7 significantly attenuated tacrolimus-stimulated (1 ng/mL, nϭ8; 10 ng/mL, nϭ8; 100 ng/mL, nϭ16; Figure 1B ) and CyA-stimulated (1 g/mL, nϭ8; 10 g/mL, nϭ16; Figure 1C ) neutrophil adhesion. Combined treatment with Jagged1 significantly attenuated the ability of Egfl7 to block neutrophil adhesion to HCAECs treated with tacrolimus (10 ng/mL, nϭ4; 100 ng/mL, nϭ4; Figure 1B ) and CyA (1 g/mL, nϭ4; 10 g/mL, nϭ8; Figure 1C ).
Egfl7 Inhibits HCAEC ICAM-1 Expression in Response to CNI
Exposure to tacrolimus (100 ng/mL) for 48 hours (nϭ4/ group) did not significantly affect total cellular ICAM-1 expression in HCAECs (82Ϯ18% of control, PϭNS); however, ICAM-1 was increased significantly in the membrane fraction (149Ϯ10% of control, PϽ0.001) by tacrolimus treatment (Figure 2 ). Cotreatment with Egfl7 (nϭ4/group) significantly attenuated the tacrolimus-induced ICAM-1 level in the membrane fraction (97Ϯ5% of control, PϽ0.001 versus tacrolimus alone; Figure 2 ).
Cell-surface HCAEC ICAM-1 expression, as detected by flow cytometry, was stimulated by both CyA (PϽ0.001, nϭ6) and tacrolimus (PϽ0.001, nϭ6) treatment ( Figures 3A  and 3B ; nϭ6/group). Treatment with Egfl7 alone (PϽ0.01 versus control, nϭ8) or concurrently with CyA (PϽ0.001 versus CyA alone, nϭ8) or tacrolimus (PϽ0.001 versus tacrolimus alone, nϭ8) significantly blocked cell-surface ICAM-1 expression ( Figures 3A and 3B) . Combined treatment with Jagged1 (nϭ4/group) significantly attenuated the ability of Egfl7 to block CNI-stimulated cell-surface ICAM-1 expression (PϽ0.01 versus CyA plus Egfl7; PϽ0.05 versus tacrolimus plus Egfl7; Figure 3C ).
Egfl7 Blocks CNI-Induced HCAEC NF-B Activation
Exposure to 6 hours of CyA (10 g/mL, nϭ4/group) significantly increased NF-B (p65) DNA-binding activity in the nuclear lysates of HCAECs (128Ϯ2% of control, PϽ0.001; Figure 4 ), and this was significantly attenuated by treatment with Egfl7 (86Ϯ3% of control, PϽ0.001 versus CyA alone; Figure 4 ; nϭ4/group). Combined treatment with Jagged1 Figure 1 . Neutrophil adhesion to human coronary artery endothelial cell (HCAEC) monolayers. A, Neutrophil adhesion to HCAECs subjected to 48 hours incubation with tacrolimus (1 to 100 ng/mL) or cyclosporine (CyA; 1 to 10 g/mL) was increased significantly compared with control (control: 20Ϯ5%, nϭ8; tacrolimus 1 ng/mL [Tac 1]: 33Ϯ10%, nϭ8; tacrolimus 10 ng/mL [Tac 10]: 41Ϯ5%, nϭ8; tacrolimus 100 ng/mL [Tac 100]: 34Ϯ2%, nϭ8; CyA 1 g/mL [CyA 1]: 38Ϯ3%, nϭ8; CyA 10 g/mL [CyA 10]: 37Ϯ3%, nϭ8; *PϽ0.001 vs control). TNF-␣ indicates tumor necrosis factor-␣; Egfl7, epidermal growth factor-like domain 7; and Jag1, Jagged1 (200 ng/mL). B, Cotreatment with Egfl7 (100 ng/mL) for 48 hours significantly inhibited neutrophil adhesion to HCAECs incubated with tacrolimus (1 ng/mL, nϭ8; 10 ng/mL, nϭ8; 100 ng/mL, nϭ16). Treatment with Jagged1 (200 ng/mL, nϭ4/group) when combined with tacrolimus (10 to 100 ng/mL) and Egfl7 (100 ng/mL) for 48 hours significantly blocked the inhibitory affect of Egfl7 on neutrophil adhesion. C, Cotreatment with Egfl7 (100 ng/mL) for 48 hours significantly inhibited neutrophil adhesion to HCAECs incubated with CyA (1 g/mL, nϭ8; 10 g/mL, nϭ16). Treatment with Jag-ged1 (200 ng/mL, nϭ4/group) when combined with CyA (1 to 10 g/mL) and Egfl7 (100 ng/mL) for 48 hours significantly blocked the inhibitory affect of Egfl7 on neutrophil adhesion. CyA 0.1 indicates CyA 0.1 g/mL.
(nϭ4/group) significantly attenuated the ability of Egfl7 to inhibit CyA-stimulated NF-B activity (105Ϯ4% of control, PϽ0.05 versus CyA plus Egfl7; Figure 4 ).
Egfl7 Does Not Affect HCAEC Viability
Treatment with CyA (10 g/mL) or tacrolimus (100 ng/mL) for 48 hours (nϭ8/group) significantly decreased HCAEC viability as measured with an XTT assay (A450-A650: control 0.83Ϯ0.03 versus CyA 0.67Ϯ0.03, PϽ0.05; versus tacrolimus 0.70Ϯ0.05, PϽ0.05; Figure 5 ). Exposure to 48 hours of Egfl7 (100 ng/mL) alone (nϭ8/group) or in combination with either CyA (10 g/mL) or tacrolimus (100 ng/mL) did not significantly affect HCAEC viability ( Figure 5 ).
Discussion
Accumulating evidence suggests that Egfl7 may have the potential to modulate the endothelial response to injury. [12] [13] [14] 16, [22] [23] [24] Endothelial injury that occurs after insults such as exposure to CNI results in decreased endothelial NO production, superoxide anion production, increased endothelin-1 production, and sensitivity to endothelin-1. [1] [2] [3] [4] [5] 25 These disturbances, in turn, stimulate the expression of inflammatory cytokines such as interleukin-6 6,7 and cell adhesion molecules such as ICAM-1. These events allow circulating neutrophils to migrate to sites of endothelial injury, where they subject local tissues, including the endothelium, to further injury. 11,26 -29 CNI-related injury is one mechanism of injury that has been implicated in the development of transplant coronary disease after heart transplantation. 30 Given the potential of Egfl7 to be a novel regulator of the coronary endothelial response to injury, we sought to determine the role that it plays in regulating the coronary endothelial response to CNI-induced injury in isolated HCAECs.
We have made the following novel observations: (1) Isolated HCAECs exposed to CNI treatment demonstrate an increased adhesiveness to neutrophils; (2) isolated HCAECs exposed to CNI demonstrate an increase in cell-surface ICAM-1 expression; (3) incubation with Egfl7 suppresses both neutrophil adhesion to and ICAM-1 production by HCAECs stimulated with CNI injury; (4) incubation with Egfl7 inhibits CyA-induced HCAEC NF-B activation; and (5) coincubation with Jagged1 attenuates the effects of Egfl7 on HCAEC adhesiveness, ICAM-1 production, and NF-B activation in response to CNI injury.
Effect of CNI and Egfl7 on Neutrophil Adhesion
We determined that exposure to CNI increases neutrophil adhesion to treated HCAECs. Inflammatory cells such as neutrophils that migrate to sites of endothelial injury are thought to be key in promoting and sustaining the arteriopathy that results from chronic CyA treatment. 31, 32 CyA has been demonstrated to increase the adhesion of leukocytes to vascular endothelium under physiological flow conditions, with the upregulation of cell adhesion molecules including ICAM-1, vascular cell adhesion molecule-1, and E-selectin implicated in this process. 32 Furthermore, both CyA and tacrolimus have been demonstrated to increase the binding of dendritic cells to endothelial cells, again with ICAM-1 and vascular cell adhesion molecule-1 implicated in this process. 33 Thus, the present finding that CNI treatment increases neutrophil adhesion to HCAECs is in keeping with these previous results. Importantly, our observation that Egfl7 has the potent ability to block neutrophil adhesion to HCAECs in Figure 2 . Human coronary artery endothelial cell (HCAEC) intercellular adhesion molecule-1 (ICAM-1) protein expression in response to tacrolimus (Tac) and epidermal growth factor-like domain 7 (Egfl7). Total cellular ICAM-1 protein expression from whole cell lysates and membrane fractions in response to incubation with tacrolimus with or without Egfl7 measured by Western blot analysis. Whole cell ICAM-1 levels were significantly decreased by incubation with Egfl7 (100 ng/mL; 58Ϯ15% of control; ‡PϽ0.01 vs control expression; nϭ4) even with cotreatment with tacrolimus (100 ng/mL; 62Ϯ3% of control;
‡PϽ0.01 vs control expression; nϭ4). Membrane fraction ICAM-1 levels were increased significantly after 48-hour incubation with tacrolimus (100 ng/mL; 149Ϯ10% of control; *PϽ0.001 vs control expression; nϭ4), which was attenuated by cotreatment with Egfl7 (100 ng/mL; 97Ϯ5% of control; †PϽ0.001 vs tacrolimus alone. Tac 100 indicates tacrolimus 100 ng/mL; TNF-␣, tumor necrosis factor-␣; and Egfl7, Egfl7 100 ng/mL. the face of CNI injury suggests that Egfl7 may be a novel target for intervention to attenuate CNI-induced vascular injury caused by neutrophil recruitment.
Effect of CNI and Egfl7 on ICAM-1 Expression
We determined that exposure to CNI led to increased cellsurface ICAM-1 expression in HCAECs. ICAM-1 is basally expressed in endothelial cells; however, cell-surface levels normally remain low. 34 On endothelial activation by stimulation from injury or exposure to inflammatory mediators, ICAM-1, as well as other cell adhesion molecules such as vascular cell adhesion molecule-1, P-selectin, and E-selectin, is translocated to the cell surface. 11, 35 These adhesion molecules play a critical role in interacting with circulating neutrophils, causing them to roll on and eventually adhere to endothelial cells. 36 Neutrophils can then transmigrate between activated endothelial cells to sites of injury, where they further propagate tissue injury and inflammation. Our finding that Egfl7 suppresses endothelial ICAM-1 levels stimulated by CNI suggests that this may be part of the mechanism by which Egfl7 inhibits neutrophil adhesion to HCAECs subjected to CNI treatment.
Effect of Egfl7 on NF-B Activation
The present study demonstrated that Egfl7 inhibits the nuclear translocation of NF-B that occurs on stimulation with CyA in HCAECs. It is well established that NF-B plays a key role in regulating the expression of endothelial cell adhesion molecules such as ICAM-1. 37 CNI has been demonstrated to have a proinflammatory effect on endothelial cells, and both CyA and tacrolimus have the ability to upregulate NF-B expression and activity. 38 -41 In unstimulated and uninjured cells, NF-B is sequestered in the cytoplasm in an inactive state by IB isoforms, IB-␣ being the most abundant isoform. On stimulation, IB is phosphorylated and degraded, which releases NF-B and allows it to translocate to the nucleus to act as an active transcription factor. Nuclear translocation of NF-B in injured endothelial cells has been implicated in the enhanced transcriptiondependent expression of cell adhesion molecules, because the promoter regions of the genes for these molecules contain NF-B-binding sites that are essential for the expression of these proteins on endothelial cells. 42 Thus, the present finding that Egfl7 inhibits activation of NF-B on CyA-induced injury suggests this may be the mechanism by which Egfl7 inhibits ICAM-1 expression.
Effect of Notch Pathway Stimulation on Egfl7 Signaling
We determined that the inhibitory effects of Egfl7 on CNI stimulated neutrophil adhesion to treated HCAECs, and CNI-stimulated ICAM-1 expression and NF-B activation were blocked by the Notch receptor agonist Jagged1. Recently, Schmidt and colleagues reported the novel finding that Egfl7 antagonizes Notch-specific signaling in neural stem cells, and moreover, they demonstrated that Egfl7 binds to Notch receptors and competitively inhibits binding of Jag-ged1 to these receptors. 18, 43 Interestingly, there is a complex cross talk that occurs between Notch and NF-B signaling, and there is evidence that Notch pathway activation results in NF-B nuclear retention and activation. 44, 45 The present finding that the effects of Egfl7 are inhibited by Jagged1 suggest that Egfl7 may be attenuating Notch signaling, which in turn may repress the nuclear retention of NF-B and explain the inhibition of NF-B activity that we observed.
Study Limitations
The present study provides evidence that Egfl7 inhibits coronary endothelial adhesiveness to neutrophils and ICAM-1 expression in an in vitro model of CNI injury, likely thorough inhibition of NF-B. Because the physiological level of Egfl7 is not currently known, we may have used a supraphysiological dose of Egfl7 that may not be entirely representative of what occurs in vivo. The potential beneficial effects of Egfl7 on attenuation of CNI injury are tentative and require further study in an in vivo model of transplantation. Although the present study demonstrated attenuated ICAM-1 expression in response to Egfl7, it does not exclude effects on other cell adhesion molecules and inflammatory signaling pathways.
Summary
In conclusion, the present study reveals that Egfl7 is a potent inhibitor of neutrophil adhesion to HCAECs subsequent to CNI-induced injury. Mechanistically, Egfl7 blocked NF-B pathway activation and ICAM-1 expression, which suggests that it may have significant antiinflammatory properties. Because Jagged1 blocked the effect of Egfl7, Notch receptor antagonism may contribute to the mechanism of action of Egfl7. Thus, we conclude that Egfl7 has the potential to be protective against CNI-induced endothelial injury incurred after cardiac transplantation and thus may modulate events that lead to the development of cardiac allograft vasculopathy. Ideally, a comprehensive understanding of the biology of Egfl7, including the regulation of its expression and the mechanism mediating its actions, will allow us to develop strategies to either manipulate its expression in vivo or target its mediating mechanisms, such as the Notch pathway. Further study will be required to determine whether Egfl7 is truly protective against transplant-related endothelial injury in a model of cardiac transplant and allograft vasculopathy. . Incubation with CyA (10 g/mL) for 6 hours significantly increased NF-B DNA-binding activity (128Ϯ2% of control; PϽ0.001; nϭ4). Cotreatment with epidermal growth factor-like domain 7 (Egfl7; 100 ng/mL) significantly blocked NF-B DNA-binding activity stimulated by CyA (86Ϯ3% of control; PϽ0.001 vs CyA alone; nϭ4). Treatment with Jag-ged1 (Jag1; 200 ng/mL, nϭ4/group) when combined with CyA (10 g/mL) and Egfl7 (100 ng/mL) for 6 hours significantly blocked the inhibitory effect of Egfl7 on NF-B DNA-binding activity (105Ϯ4% of control; PϽ0.05 vs CyAϩEgfl7). CyA indicates CyA 10 g/mL.
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Figure 5.
Human coronary artery endothelial cell (HCAEC) viability assessed by XTT assay. Incubation with epidermal growth factor-like domain 7 (Egfl7; 100 ng/mL) for 48 hours did not significantly affect cell viability compared with control (A450 -A650: 0.84Ϯ0.03 vs 0.83Ϯ0.03, PϾ0.05, nϭ8/group). Although 48 hours of treatment with either CyA (10 g/mL) or tacrolimus (Tac) 100 ng/mL significantly decreased cell viability compared with control (A450 -A650: control 0.83Ϯ0.03 vs CyA 0.67Ϯ0.03, *PϽ0.05; vs tacrolimus 0.70Ϯ0.05, *PϽ0.05; nϭ8/group), coincubation with Egfl7 (100 ng/mL) did not significantly affect this decrease in viability.
